Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2025-01-27 Regulatory Filings
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Innate Pharma announcing the initiation of a Phase 1 clinical trial for a new drug candidate (IPH4502). It provides details on the drug's mechanism, the trial design, and quotes from company leadership. This type of corporate announcement regarding clinical trial progress does not fit into specific financial reporting categories like 10-K or ER, nor is it a report publication announcement. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general corporate regulatory announcement.
2025-01-27 French
6-K
Foreign Filer Report
2025-01-21 English
Inside Information / Other news releases
Investor Presentation Classification · 1% confidence The document is a press release titled "INNATE PHARMA ANNOUNCES NECTIN-4 ANTIBODY DRUG CONJUGATE INVESTOR AND ANALYST EVENT IN NEW YORK." It details the date, time, and registration information for an upcoming event where the company will discuss its IPH4502 program. This is not a full financial report (like 10-K or IR), an earnings release (ER), or a proxy statement (DEF 14A). It is an announcement about an event intended for investors and analysts to discuss strategy and clinical advancements. This fits best under Investor Presentation (IP) if it were the presentation itself, but since it is an announcement *of* an event where presentations will occur, and it contains general company and product updates, it functions similarly to an Investor Presentation announcement or a general corporate update. However, given the options, the content is primarily focused on presenting scientific and clinical data to investors, which aligns closely with the purpose of an Investor Presentation (IP). Since it is an announcement *about* the event rather than the presentation materials themselves, it could potentially be RPA or RNS, but the core subject matter is the presentation of investment-relevant data. Given the focus on a specific drug program and strategy update for investors, classifying it as an Investor Presentation (IP) is the most contextually accurate choice, as these announcements often precede or accompany the actual presentation materials.
2025-01-21 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a press release ("COMMUNIQUÉ DE PRESSE") announcing a specific event: an Analyst and Investor Event to present the company's strategy regarding Antibody-Drug Conjugates (ADCs), focusing on the IPH4502 program. This announcement details the date, time, registration link, and background information on the science and the company. It is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing detailing a transaction or result (like DIRS or DIV). Since the core purpose is to inform investors about an upcoming presentation focused on strategy and pipeline assets, it aligns best with an Investor Presentation (IP) announcement, or more generally, a communication aimed at investors about future strategy/data. Given the options, while it announces a future presentation, the content itself is a detailed strategic update and scientific overview, which is characteristic of an Investor Presentation (IP). However, since it is an *announcement* of an event where an IP might be given, and it contains significant strategic and scientific detail, it is a strong candidate for IP. If the document were the actual presentation slides, IP would be certain. As a press release announcing the event and providing context, it functions as a high-level investor communication. Given the focus on presenting strategy and clinical programs (IPH4502), 'Investor Presentation' (IP) is the most fitting category for the *topic* being communicated, even if it's the announcement vehicle.
2025-01-21 French
6-K
Foreign Filer Report
2025-01-16 English
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF DECEMBER 31, 2024" and is dated January 16, 2025. It explicitly states that it is released pursuant to the French 'Code de Commerce' and the AMF General Regulation to report the total number of shares outstanding and voting rights as of a specific date (December 31, 2024). This type of periodic disclosure regarding share capital structure and voting rights is a specific regulatory requirement, often related to major shareholding notifications or general capital structure updates. Since it is a formal announcement detailing the exact number of shares and voting rights, it fits best under the category related to changes in share capital or major ownership disclosures. Given the options, 'Major Shareholding Notification' (MRQ) is the closest fit as it deals with the total share count which underpins threshold crossings, or 'Share Issue/Capital Change' (SHA). However, the content is a mandatory periodic disclosure of the total share count, which is a prerequisite for major shareholding reports (MRQ) and is often filed alongside or as a standalone requirement related to capital structure. Since it is not announcing a new issue (SHA) but reporting the current state of shares/rights, and it references AMF regulations for threshold calculations, it aligns closely with the spirit of major ownership reporting. If a more specific 'Share Capital Disclosure' existed, it would be preferred. Between the available options, 'Major Shareholding Notification' (MRQ) captures the essence of reporting share counts relevant to ownership thresholds, although it is a general capital structure update. Alternatively, since it is a formal regulatory disclosure not fitting other specific categories like ER, 10-K, or DIV, it could fall under RNS, but MRQ is more specific to the content. Given the focus on the total number of shares and voting rights as required by AMF regulations (which govern shareholding thresholds), MRQ is the most appropriate specific classification.
2025-01-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.